Citius Pharmaceuticals Business Summary

Citius Pharmaceuticals, Inc. (CTXR) is a commercial-stage biopharmaceutical company that generates revenue through the direct sale of proprietary therapeutics, international licensing agreements, and contract manufacturing organization (CMO) services. The company operates across three primary business segments: Oncology, led by its 75%-owned subsidiary Citius Oncology (CTOR); Critical Care, focused on its late-stage anti-infective pipeline; and Specialty Prescription products. As of February 2026, the company’s revenue model is anchored by the commercial launch of LYMPHIR™ (denileukin diftitox-cxdl) for cutaneous T-cell lymphoma and an exclusive EU distribution partnership with Uniphar. Citius competes directly with oncology and critical care peers such as Tevogen Bio, InflaRx, TScan Therapeutics, and PMV Pharmaceuticals, positioning itself as a high-growth specialty player targeting underserved orphan indications and hospital-based infections. The leadership team is anchored by Executive Chairman and CEO Leonard Mazur, a serial entrepreneur who previously co-founded Akrimax Pharmaceuticals and Triax Pharmaceuticals, and Executive Vice Chairman Myron Holubiak, the former President of Roche Laboratories. Key executives include CFO and Chief Business Officer Jaime Bartushak, a co-founder of Leonard-Meron Biosciences, and Chief Medical Officer Dr. Myron Czuczman, who previously served as a therapeutic area head at Celgene. The company’s strategic direction is supported by a board featuring industry veterans like Dennis M. McGrath (President of PAVmed) and notable institutional backing from investors such as MBX Capital, Heights Capital Management, and Vanguard.